Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu-177 FAP-2286 in Carcinoma of Unknown Primary
NCT07434180Phase 2Not yet recruiting
- Sponsor
- Peter MacCallum Cancer Centre
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AAA614 in carcinoma of unknown primary (CUP), sponsored by Peter MacCallum Cancer Centre. Primary endpoint: Overall Response Rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
AAA614
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT07434180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07434180.